Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS636 monotherapy and HS636 plus nab-paclitaxel in advanced triple-negative breast cancer
ChiCTR2100051705Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sudubrilimab in triple-negative breast cancer (TNBC) (6 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Incidence and severity of adverse events and Objective response rate. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
sudubrilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2100051705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051705.